Table 4.

Hazard ratios (HR) for disease-specific mortality with 95% confidence intervals (CI) in primary small bowel neuroendocrine tumors stratified by MCT4 intensity (low/high), MCT4 percentage (low/high), and MCT4 score.

MCT4 Intensity
Primary tumors	No. of patients	Low HR (95%CI)	High HR (95%CI)
Crude	104	1.00 (reference)	0.13 (0.02–0.99)
Adjusted	104	1.00 (reference)	0.19 (0.03–1.48)
MCT4 percentage
Primary tumors	No. of patients	Low, HR (95%CI)	High, HR (95%CI)
Crude	104	1.00 (reference)	0.44 (0.18–1.05)
Adjusted	104	1.00 (reference)	0.23 (0.09–0.61)
MCT4 score
Primary tumors	No. of patients	Score 0, HR (95%CI)	Score 1, HR (95%CI)	Score 2, HR (95%CI)
Crude	104	1.00 (reference)	0.87 (0.36–2.06)	0.00 (0.00–0.00)
Adjusted	104	1.00 (reference)	0.41 (0.16–1.10)	0.00 (0.00–0.00)

Adjusted for age (continuous), sex (male/female), stage (I-II, III, IV), grade of differentiation (G1 or G2), somatostatin therapy (no/yes) and sample type (surgical resection specimen or biopsy).